EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia

On November 5, 2020, a marketing authorization valid through the European Union (EU) was issued for acalabrutinib monotherapy or acalabrutinib in combination with obinutuzumab (AcalaObi) in adult patients with treatment‐naïve (TN) chronic lymphocytic leukemia (CLL) and also for acalabrutinib monothe...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Delgado, Julio, Josephson, Filip, Camarero, Jorge, Garcia‐Ochoa, Blanca, Lopez‐Anglada, Lucia, Prieto‐Fernandez, Carolina, van Hennik, Paula B., Papadouli, Irene, Gisselbrecht, Christian, Enzmann, Harald, Pignatti, Francesco
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Inc. 2021
Konular:
Regulatory Issues: EMA
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7930415/
https://ncbi.nlm.nih.gov/pubmed/33486852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13685
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller